Search

Your search keyword '"Schanz, Urs"' showing total 17 results
Start Over Author "Schanz, Urs" Journal bone marrow transplantation
17 results on '"Schanz, Urs"'

1. Correction: Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan

Author

Seydoux, Claire, primary, Uppugunduri, Chakradhara Rao Satyanarayana, additional, Medinger, Michael, additional, Nava, Tiago, additional, Halter, Joerg, additional, Heim, Dominik, additional, Chalandon, Yves, additional, Schanz, Urs, additional, Nair, Gayathri, additional, Cantoni, Nathan, additional, Passweg, Jakob R., additional, and Ansari, Marc, additional

Published
2023
Full Text
View/download PDF

3. Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan

Author

Seydoux, Claire, primary, Uppugunduri, Chakradhara Rao Satyanarayana, additional, Medinger, Michael, additional, Nava, Tiago, additional, Halter, Joerg, additional, Heim, Dominik, additional, Chalandon, Yves, additional, Schanz, Urs, additional, Nair, Gayathri, additional, Cantoni, Nathan, additional, Passweg, Jakob R., additional, and Ansari, Marc, additional

Published
2023
Full Text
View/download PDF

4. Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT

Author

Al Hamed, Rama, Labopin, Myriam, Wu, Depei, Gedde-Dahl, Tobias, Aljurf, Mahmoud, Forcade, Edouard, Salmenniemi, Urpu, Passweg, Jakob, Maertens, Johan, Pabst, Thomas, Versluis, Jurjen, Itäla-Remes, Maija, Huang, Xiao-Jun, Van Gorkom, Gwendolyn, Schroeder, Thomas, Sanz, Jaime, Blaise, Didier, Reményi, Péter, Schanz, Urs, Esteve, Jordi, Gorin, Norbert-Claude, Ciceri, Fabio, and Mohty, Mohamad

Abstract

Core-binding factor acute myeloid leukemia (CBF-AML) represents 12–15% of all AML cases. Although CBF positivity infers a survival advantage, overall survival (OS) remains dismal. Treatment is with cytarabine/anthracycline-based chemotherapy induction followed by high-dose cytarabine (HiDAC) consolidation. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is reserved for relapse or for patients having not achieved MRD-negativity at high risk for relapse. The role of SCT in first complete remission (CR1) remains controversial and is considered in high risk conditions. In this retrospective, multi-national, European Society for Blood and Marrow Transplantation (EBMT)-based study, we identified 1901 patients with de novo CBF-AML who received an allo-SCT or autologous transplantation (ASCT) in CR1. 65.5% harbored t(8;21) and 34.4% inv(16). In this group, the majority (77%) were treated with allo-SCT in CR1. In multivariate analysis, treatment with allo-SCT was an independent and significant, negative predictor of NRM and OS (HR 4.26, p< 0.0001 and HR 1.67, p= 0.003) and among patients treated with allo-SCT, those treated with MSD had the best outcomes, comparable to those treated with ASCT. There was no interaction between the type of transplant and MRD status at time of SCT. In both, MRD-negative and MRD-positive groups, NRM was worse in the allo-SCT group (MRD−: 12.9% vs5.2%, p= 0.007; MRD+: 10.6% vs0%, p= 0.004). We therefore demonstrated that consolidation in CR1 with allo-SCT results in worse outcomes than ASCT. Whether consolidation with ASCT yields better outcomes than chemotherapy alone or chemotherapy in combination with Gemtuzumab Ozogamicin is yet to be investigated.

Published
2024
Full Text
View/download PDF

5. Correction: High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation

Author

Buhler, Stéphane, primary, Baldomero, Helen, additional, Ferrari-Lacraz, Sylvie, additional, Nunes, José Manuel, additional, Sanchez-Mazas, Alicia, additional, Massouridi-Levrat, Stravroula, additional, Heim, Dominik, additional, Halter, Jörg, additional, Nair, Gayathri, additional, Chalandon, Yves, additional, Schanz, Urs, additional, Güngör, Tayfun, additional, Nicoloso, Grazia, additional, Tiercy, Jean-Marie, additional, Passweg, Jakob, additional, and Villard, Jean, additional

Published
2020
Full Text
View/download PDF

6. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Author

Snowden, John A., primary, Saccardi, Riccardo, additional, Orchard, Kim, additional, Ljungman, Per, additional, Duarte, Rafael F., additional, Labopin, Myriam, additional, McGrath, Eoin, additional, Brook, Nigel, additional, de Elvira, Carmen Ruiz, additional, Gordon, Debra, additional, Poirel, Hélène A., additional, Ayuk, Francis, additional, Beguin, Yves, additional, Bonifazi, Francesca, additional, Gratwohl, Alois, additional, Milpied, Noel, additional, Moore, John, additional, Passweg, Jakob, additional, Rizzo, J. Douglas, additional, Spellman, Stephen R., additional, Sierra, Jorge, additional, Solano, Carlos, additional, Sanchez-Guijo, Fermin, additional, Worel, Nina, additional, Gusi, Andreu, additional, Adams, Gillian, additional, Balan, Theodor, additional, Baldomero, Helen, additional, Macq, Gilles, additional, Marry, Evelyne, additional, Mesnil, Florence, additional, Oldani, Elena, additional, Pearce, Rachel, additional, Perry, Julia, additional, Raus, Nicole, additional, Schanz, Urs, additional, Tran, Steven, additional, Wilcox, Leonie, additional, Basak, Grzegorz W., additional, Chabannon, Christian, additional, Corbacioglu, Selim, additional, Dolstra, Harry, additional, Kuball, Jürgen, additional, Mohty, Mohamad, additional, Lankester, Arjan, additional, Montoto, Sylvia, additional, Nagler, Arnon, additional, Styczynski, Jan, additional, Yakoub-Agha, Ibrahim, additional, de Latour, Regis Peffault, additional, Kroeger, Nicolaus, additional, Brand, Ronald, additional, de Wreede, Liesbeth C., additional, van Zwet, Erik, additional, and Putter, Hein, additional

Published
2019
Full Text
View/download PDF

7. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Author

Snowden, John A., primary, Saccardi, Riccardo, additional, Orchard, Kim, additional, Ljungman, Per, additional, Duarte, Rafael F., additional, Labopin, Myriam, additional, McGrath, Eoin, additional, Brook, Nigel, additional, de Elvira, Carmen Ruiz, additional, Gordon, Debra, additional, Poirel, Hélène A., additional, Ayuk, Francis, additional, Beguin, Yves, additional, Bonifazi, Francesca, additional, Gratwohl, Alois, additional, Milpied, Noel, additional, Moore, John, additional, Passweg, Jakob, additional, Rizzo, J. Douglas, additional, Spellman, Stephen R., additional, Sierra, Jorge, additional, Solano, Carlos, additional, Sanchez-Guijo, Fermin, additional, Worel, Nina, additional, Gusi, Andreu, additional, Adams, Gillian, additional, Balan, Theodor, additional, Baldomero, Helen, additional, Macq, Gilles, additional, Marry, Evelyne, additional, Mesnil, Florence, additional, Oldani, Elena, additional, Pearce, Rachel, additional, Perry, Julia, additional, Raus, Nicole, additional, Schanz, Urs, additional, Tran, Steven, additional, Wilcox, Leonie, additional, Basak, Grzegorz W., additional, Chabannon, Christian, additional, Corbacioglu, Selim, additional, Dolstra, Harry, additional, Kuball, Jürgen, additional, Mohty, Mohamad, additional, Lankester, Arjan, additional, Montoto, Sylvia, additional, Nagler, Arnon, additional, Styczynski, Jan, additional, Yakoub-Agha, Ibrahim, additional, de Latour, Regis Peffault, additional, Kroeger, Nicolaus, additional, Brand, Ronald, additional, de Wreede, Liesbeth C., additional, van Zwet, Erik, additional, and Putter, Hein, additional

Published
2019
Full Text
View/download PDF

8. High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation

Author

Buhler, Stéphane, primary, Baldomero, Helen, additional, Ferrari-Lacraz, Sylvie, additional, Nunes, José Manuel, additional, Sanchez-Mazas, Alicia, additional, Massouridi-Levrat, Stravroula, additional, Heim, Dominik, additional, Halter, Jörg, additional, Nair, Gayathri, additional, Chalandon, Yves, additional, Schanz, Urs, additional, Güngör, Tayfun, additional, Nicoloso, Grazia, additional, Tiercy, Jean-Marie, additional, Passweg, Jakob, additional, and Villard, Jean, additional

Published
2019
Full Text
View/download PDF

9. Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates

Author

Sava, Mihaela, Bättig, Veronika, Gerull, Sabine, Passweg, Jakob R., Khanna, Nina, Garzoni, Christian, Gerber, Bernhard, Mueller, Nicolas J., Schanz, Urs, Berger, Christoph, Chalandon, Yves, van Delden, Christian, Neofytos, Dionysios, Stampf, Susanne, Franzeck, Fabian C., and Weisser, Maja

Published
2022
Full Text
View/download PDF

10. Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Author

Sellner, Leopold, Schetelig, Johannes, Koster, Linda, Choi, Goda, Blaise, Didier, Beelen, Dietrich, Schianca, Fabrizio Carnevale, Passweg, Jakob, Schanz, Urs, Gyan, Emmanuel, Sora, Federica, Kröger, Nicolaus, Wulf, Gerald. G., Van Gorkom, Gwendolyn, Mayer, Jiri, Orvain, Corentin, Bourhis, Jean Henri, Jindra, Pavel, Potter, Victoria, Zallio, Francesco, Vandenberghe, Elisabeth, Robinson, Stephen, Hayden, Patrick J., Yakoub-Agha, Ibrahim, Montoto, Silvia, and Dreger, Peter

Published
2020
Full Text
View/download PDF

11. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Author

Snowden, John A., Saccardi, Riccardo, Orchard, Kim, Ljungman, Per, Duarte, Rafael F., Labopin, Myriam, McGrath, Eoin, Brook, Nigel, de Elvira, Carmen Ruiz, Gordon, Debra, Poirel, Hélène A., Ayuk, Francis, Beguin, Yves, Bonifazi, Francesca, Gratwohl, Alois, Milpied, Noel, Moore, John, Passweg, Jakob, Rizzo, J. Douglas, Spellman, Stephen R., Sierra, Jorge, Solano, Carlos, Sanchez-Guijo, Fermin, Worel, Nina, Gusi, Andreu, Adams, Gillian, Balan, Theodor, Baldomero, Helen, Macq, Gilles, Marry, Evelyne, Mesnil, Florence, Oldani, Elena, Pearce, Rachel, Perry, Julia, Raus, Nicole, Schanz, Urs, Tran, Steven, Wilcox, Leonie, Basak, Grzegorz W., Chabannon, Christian, Corbacioglu, Selim, Dolstra, Harry, Kuball, Jürgen, Mohty, Mohamad, Lankester, Arjan, Montoto, Sylvia, Nagler, Arnon, Styczynski, Jan, Yakoub-Agha, Ibrahim, de Latour, Regis Peffault, Kroeger, Nicolaus, Brand, Ronald, de Wreede, Liesbeth C., van Zwet, Erik, and Putter, Hein

Abstract

In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT.

Published
2020
Full Text
View/download PDF

12. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study

Author

Ghilardi, Guido, Pabst, Thomas, Jeker, Barbara, Müller, Rouven, Cairoli, Anne, Müller, Antonia M. S., Bargetzi, Mario, Hitz, Felicitas, Baldomero, Helen, Heim, Dominik, Schmidt, Adrian, Rossi, Davide, Ghielmini, Michele, Wannesson, Luciano, Lerch, Erika, Samaras, Panagiotis, Schanz, Urs, Passweg, Jakob R., Stussi, Georg, Kleber, Martina, and Gerber, Bernhard

Abstract

The optimal melphalan dose prior to autologous stem cell transplantation (ASCT) is not known for elderly multiple myeloma (MM) patients. We analyzed data of all MM patients ≥65 years (n= 388) enrolled in the observational Swiss Blood Stem Cell Transplantation Registry. The median age was 67 years (65–77). Single ASCT was performed in 344 (88.7%) patients, with 259 patients (75.3%) receiving a melphalan dose of 200 mg/m2(MEL200), and 85 patients (24.7%) receiving lower doses (MELlow) (median 140 mg/m2, range 70−180 mg/m2). MEL200 patients were slightly younger, and had a better renal function, but did not differ with regards to ISS stage, cytogenetic risk, remission status, and KPS. Overall mortality at day 100 was 1.5% without differences between the MEL groups (p= 0.621). Median progression-free survival (PFS) in the MEL200 and the MELlow group was 27.7 and 22.1 months, respectively (p= 0.294). Median overall survival (OS) in the MEL200 and in MELlow group was 91.2 and 61.2 months (p= 0.015). However, multivariate analysis showed no significant association of the melphalan dose and OS (HR 0.734; CI95% 0.264–2.038; p= 0.553). In conclusion, our data reveal no significant differences in safety and PFS for elderly myeloma patients treated with MEL200 or with lower MEL doses.

Published
2019
Full Text
View/download PDF

13. Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Author

Sellner, Leopold, Schetelig, Johannes, Koster, Linda, Choi, Goda, Blaise, Didier, Beelen, Dietrich, Schianca, Fabrizio Carnevale, Passweg, Jakob, Schanz, Urs, Gyan, Emmanuel, Sora, Federica, Kröger, Nicolaus, Wulf, Gerald. G., Van Gorkom, Gwendolyn, Mayer, Jiri, Orvain, Corentin, Bourhis, Jean Henri, Jindra, Pavel, Potter, Victoria, Zallio, Francesco, Vandenberghe, Elisabeth, Robinson, Stephen, Hayden, Patrick J., Yakoub-Agha, Ibrahim, Montoto, Silvia, and Dreger, Peter

Published
2024
Full Text
View/download PDF

14. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Author

Snowden, John A., Saccardi, Riccardo, Orchard, Kim, Ljungman, Per, Duarte, Rafael F., Labopin, Myriam, McGrath, Eoin, Brook, Nigel, de Elvira, Carmen Ruiz, Gordon, Debra, Poirel, Hélène A., Ayuk, Francis, Beguin, Yves, Bonifazi, Francesca, Gratwohl, Alois, Milpied, Noel, Moore, John, Passweg, Jakob, Rizzo, J. Douglas, Spellman, Stephen R., Sierra, Jorge, Solano, Carlos, Sanchez-Guijo, Fermin, Worel, Nina, Gusi, Andreu, Adams, Gillian, Balan, Theodor, Baldomero, Helen, Macq, Gilles, Marry, Evelyne, Mesnil, Florence, Oldani, Elena, Pearce, Rachel, Perry, Julia, Raus, Nicole, Schanz, Urs, Tran, Steven, Wilcox, Leonie, Basak, Grzegorz W., Chabannon, Christian, Corbacioglu, Selim, Dolstra, Harry, Kuball, Jürgen, Mohty, Mohamad, Lankester, Arjan, Montoto, Sylvia, Nagler, Arnon, Styczynski, Jan, Yakoub-Agha, Ibrahim, de Latour, Regis Peffault, Kroeger, Nicolaus, Brand, Ronald, de Wreede, Liesbeth C., van Zwet, Erik, and Putter, Hein

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020
Full Text
View/download PDF

16. Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates.

Author

Sava M, Bättig V, Gerull S, Passweg JR, Khanna N, Garzoni C, Gerber B, Mueller NJ, Schanz U, Berger C, Chalandon Y, van Delden C, Neofytos D, Stampf S, Franzeck FC, and Weisser M

Subjects
Humans, Cohort Studies, Switzerland epidemiology, Transplantation, Homologous, Transplant Recipients, Sepsis, Hematopoietic Stem Cell Transplantation adverse effects
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results